Kallikrein
KLK; Kallikrein-related peptidase
Kallikrein is a serine protease that plays a crucial role in the kallikrein-kinin system. Plasma kallikrein, specifically expressed in hepatocytes, acts on high molecular weight kininogen to release bradykinin, which is involved in regulating vascular tone, inflammatory response, and endogenous blood coagulation and fibrinolysis. Tissue kallikrein, widely distributed in various tissues such as the lung, kidney, and brain, acts on low molecular weight kininogen to produce kinin, participating in processes like blood pressure regulation, electrolyte balance, and neuronal protection. Additionally, kallikrein can bind to LDLR, promoting its lysosomal degradation, and interact with ASICs to affect neuronal function in the central nervous system. Dysregulation of kallikrein activity is associated with various diseases including heart disease, kidney disease, and cancer[1][2].
References:
- [1]. Raspi G. Kallikrein and kallikrein-like proteinases: purification and determination by chromatographic and electrophoretic methods. J Chromatogr B Biomed Appl. 1996 Sep 20;684(1-2):265-87. [Content Brief]
- [2]. Yousef GM, et al. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001 Apr;22(2):184-204. [Content Brief]
Kallikrein Isoform Specific Products
All Product Categories
-
Kallikrein Related Products (64)
Related Products (64)
-
Antibodies (4)
-
Kallikrein Isoform Comparison
-
Berotralstat dihydrochloride (Standard)
0 ImagesCat. No.: HY-109127ARCAS No.: 1809010-52-3Synonyms: BCX7353 dihydrochloride (Standard)Berotralstat dihydrochloride (Standard) is the analytical standard of Berotralstat (dihydrochloride) (HY-109127A). This product is intended for research and analytical applications. Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.
-
Evrisiran
0 ImagesCat. No.: HY-185925CAS No.: 3110420-82-8Evrisiran is a prekallikrein synthesis reducer that has been studied for its potential use in hereditary angioedema.
-
Sebetralstat hydrochloride
0 ImagesCat. No.: HY-132830ACAS No.: 2163789-76-0Synonyms: KVD900 hydrochlorideSebetralstat hydrochloride (KVD900 hydrochloride) is an orally active and selective plasma kallikrein inhibitor, with an IC50 of 6.0 nM and a Ki of 3.0 nM against the human target. Sebetralstat hydrochloride binds to the active site of plasma kallikrein, inducing a conformational flip of Trp215 to form a U-shaped conformation; its P1 group interacts with the S1 pocket through hydrophobic interactions and displacement of high-energy water molecules, independent of the Asp189 ionic bond. Sebetralstat hydrochloride inhibits plasma kallikrein-kinin system activation in whole plasma, rapidly relieves laryngeal and abdominal attack symptoms of hereditary angioedema (HAE-C1INH), and reduces attack severity. Sebetralstat hydrochloride can be used in research related to hereditary angioedema (HAE).
-
KKI-5
0 ImagesCat. No.: HY-P0237CAS No.: 97145-43-2KKI-5 is a specific inhibitor of tissue kallikrein. KKI-5 can attenuate breast cancer cell invasion.
